American Association for Cancer Research

Program

Advances in Ovarian Cancer Research 2013

*Short talks from proffered papers

WEDNESDAY, SEPTEMBER 18

Educational Session

1:30 p.m.-3:30 p.m.

Mining the TCGA database 
Douglas A. Levine, Memorial Sloan-Kettering Cancer Center, New York, NY

Cell lines as ovarian cancer models: Insights from molecular profiles in TCGA and CCLE
Nikolaus Schultz, Memorial Sloan-Kettering Cancer Center, New York, NY

Break

3:30 p.m.-3:50 p.m.

Educational Session (continued)

3:50 p.m.-5:50 p.m.

Biomarker development
David G. Huntsman, The University of British Columbia, Vancouver, BC, Canada

Bringing a drug from development to the clinic
Carol A. Aghajanian, Memorial Sloan-Kettering Cancer Center, New York, NY

Dinner on Own

5:50 p.m.-7:00 p.m.

Welcoming Remarks and Keynote Talks

7:00 p.m.-9:00 p.m.

Forty years of developmental therapeutics in ovarian cancer
Carol A. Aghajanian, Memorial Sloan-Kettering Cancer Center, New York, NY

In-tumor screening for novel targets in papillary serous ovarian cancer
David M. Livingston, Dana-Farber Cancer Institute, Boston, MA

Opening Reception

9:00 p.m.-10:30 p.m.

 

Thursday, September 19

Continental Breakfast

7:00 a.m.-8:00 a.m.

Welcome and Conference Overview

8:00 a.m.-8:10 a.m.

Douglas A. Levine, Memorial Sloan-Kettering Cancer Center, New York, NY

Session 1: The Origins of Ovarian Cancer

Session Chairperson: Robert J. Kurman, Johns Hopkins Medical Institutes, Baltimore, MD
8:10 a.m.-10:10 a.m.

A dualistic model of ovarian carcinogenesis
Robert J. Kurman

Discovering the distal fallopian tube as the origin for high-grade serous ovarian cancer
Ronny I. Drapkin, Dana-Farber Cancer Institute, Boston, MA

Murine models of nonserous ovarian cancer: Effects of mutant Trp53, Pik3ca, and Arida1a in a model of endometrioid carcinoma based on Wnt and PI3K/Akt pathway defects
Kathleen R. Cho, University of Michigan Medical School, Ann Arbor, MI

Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in BRCA/p53 models*
Daniela Dinulescu, Brigham and Women's Hospital, Boston, MA

Cyclin E1 deregulation occurs early during fallopian tube tumorigenesis and promotes secretory cell transformation*
Alison Karst, Dana-Farber Cancer Institute, Boston, MA

Break

10:10 a.m.-10:30 a.m.

Session 2: Genomic Classification of Ovarian Cancer

Session Chairperson: James D. Brenton, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom
10:30 a.m.-12:30 p.m.

Determinants of clinical outcome in ovarian cancer
David D. Bowtell, Peter MacCallum Cancer Centre, Melbourne, Australia

Discovering drivers in rare ovarian subtypes
David G. Huntsman, BC Cancer Foundation, Vancouver, BC, Canada

Pathway-directed therapy
Douglas A. Levine, Memorial Sloan-Kettering Cancer Center, New York, NY

Oxidants and antioxidants in the follicular fluid in initiation of fimbriae carcinogenesis*
Hsuan-Shun Huang, Cervical Cancer Prevention Center, Tzu Chi University, Hualien, Taiwan

DNA-PK inhibition resensitizes ovarian cancer cells to cisplatin in vivo and is associated with modulation of AKT pathway signaling*
Euan Stronach, Imperial College London, London, United Kingdom

Lunch on Own/Free Time

12:30 p.m.-2:00 p.m.

Poster Viewing:
Posters to be presented in Poster Session A will be available for viewing throughout the day 12:30 p.m.-7:00 p.m.

Session 3: High-Throughput Analysis in Ovarian Cancer

Session Chairperson: Sandra Orsulic, Cedars-Sinai Medical Center, Los Angeles, CA
2:00 p.m.-3:30 p.m.

Comprehensive proteomic analyses of TCGA ovarian cancer specimens: Update from CPTAC
Karin D. Rodland, Pacific Northwest National Laboratory, Richland, WA

Functional genomics of ovarian cancer
Gordon B. Mills, The University of Texas MD Anderson Cancer Center, Houston, TX

Using publicly available databases for the functional characterization of cancer genes
Sandra Orsulic

Keynote Address

3:30 p.m.-4:15 p.m.

Ovarian cancer: Time for a new paradigm
Robert F. Ozols, Fox Chase Cancer Center, Philadelphia, PA

Poster Session A/Reception

4:30 p.m.-6:30 p.m.

Dinner on Own/Evening Off

6:30 p.m.-

 

Friday, September 20

Continental Breakfast
Mentoring Roundtable Session 1

7:00 a.m.-8:00 a.m.

Session 4: Therapeutic Opportunities from DNA Repair Deficiency

Session Chairperson: Douglas A. Levine, Memorial Sloan-Kettering Cancer Center, New York, NY
8:00 a.m.-10:00 a.m.

The Fanconi anemia-BRCA pathway and chemosensitivity of cancer cells
Toshiyasu Taniguchi, Fred Hutchinson Cancer Research Center, Seattle, WA

Exploiting the translational and functional opportunities for homologous recombination deficiency
Richard J. Edmondson, Newcastle University Medical School, Newcastle upon Tyne, United Kingdom

PARP inhibitors in ovarian cancer: Clinical trial update
Katherine Bell-McGuinn, Memorial Sloan-Kettering Cancer Center, New York, NY

In vivo antitumor activity of the PARP inhibitor Niraparib (MK-4827) in homologous recombination deficient and proficient ovarian cancer*
Mariam Al Hilli, Mayo Clinic, Rochester, MN

Ovarian cancers harbor defects in nonhomologous end joining resulting in error prone repair and resistance to Rucaparib*
Aiste McCormick, Northern Institute for Cancer Research, Newcastle Upon Tyne, Tyne and Wear, United Kingdom

Break

10:00 a.m.-10:30 a.m.

Poster Viewing:
Posters to be presented in Poster Session B will be available for viewing throughout the day 10:00 a.m.-6:00 p.m.

Session 5: Targeting Drug Resistance

Session Chairperson: David G. Huntsman, The University of British Columbia, Vancouver, BC, Canada
10:30 a.m.-12:30 p.m.

Targeting acquired platinum resistance in ovarian cancer
Hani Gabra, Imperial College London, London, United Kingdom

Targeting cancer stem cells to overcome chemotherapy resistance
Ronald J. Buckanovich, University of Michigan, Ann Arbor, MI

Targeting the methylome for epigenetic resensitization of ovarian cancer
Kenneth P. Nephew, Indiana University School of Medicine, Bloomington, IN

Targeting CD24+ ovarian cancer stem-like cells in a transgenic murine model of ovarian cancer restricts metastasis*
Daniela Burgos-Ojeda, University of Michigan, Ann Arbor, MI

HNF1beta confers resistance to oxidative stress of ovarian clear cell carcinoma*
Yasuaki Amano, Graduate School of Medicine, Kyoto University, Kyoto, Japan

Poster Session B/Lunch

12:30 p.m.-2:30 p.m.

Session 6: Clinical Implications of Intratumoral Heterogeneity

Session Chairperson: Hani Gabra, Imperial College London, London, United Kingdom
2:30 p.m.-4:30 p.m.

Evolutionary dynamics of high-grade serous ovarian cancer genomes across anatomic space and time
Sohrab P. Shah, BC Cancer Agency Vancouver Centre, Vancouver, BC, Canada

Intratumoral heterogeneity and drug response in high-grade serous carcinoma 
James D. Brenton, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom

Analyzing the cellular basis for heterogeneity in serous ovarian carcinoma
Benjamin J. Neel, University of Toronto Ontario Cancer Institute, Toronto, ON, Canada

Cellular heterogeneity of ovarian carcinoma cells and its impact on tumor behavior*
Suha Naffar-Abu Amara, Harvard Medical School, Boston, MA

Intra- and intertumor heterogeneity in epithelial ovarian cancer: Consequences for biomarker-dependent stratification of therapies*
Rachel O'Donnell, Northern Gynaecological Oncology Centre, Gateshead, United Kingdom

Panel Discussion: Survivorship Issues (Sponsored by the Foundation for Women's Cancer)

Moderator: Douglas A. Levine, Memorial Sloan-Kettering Cancer Center, New York, NY

4:30 p.m.-5:30 p.m.

Panelists:

  • Cancer Survivors:
    Jennie McGihon, Four-year ovarian and uterine cancer survivor, Co-Chair, 2013 National Race to End Women's Cancer, Alexandria, VA
    Patricia Goldman, Ovarian Cancer National Alliance, Washington, DC
  • Physician Scientists:
    David G. Huntsman, The University of British Columbia, Vancouver, BC, Canada
    James D. Brenton, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom

Dinner on Own/Evening Off

5:30 p.m.-

 

Saturday, September 21

Continental Breakfast
Mentoring Roundtable Session 2

7:00 a.m.-8:00 a.m.

Session 7: Tumor Microenvironment

Session Chairperson: Sandra Orsulic, Cedars-Sinai Medical Center, Los Angeles, CA
8:00 a.m.-10:00 a.m.

Causes and consequences of cancer-associated thrombocytosis
Anil K. Sood, The University of Texas MD Anderson Cancer Center, Houston, TX

Targeting the inflammatory cytokine network of serous ovarian cancer
Frances R. Balkwill, Barts Cancer Institute, London, United Kingdom

Microenvironmental regulation of metastasis
Ernst R. Lengyel, University of Chicago, Chicago, IL

Ovarian cancer cells activate the mesothelium in the peritoneal microenvironment promoting fibronectin production and the early steps of metastasis*
Hilary Kenny, University of Chicago, Chicago, IL

Immunomodulatory effects of 5-Azacyditine in ovarian cancer cell lines*
Katherine Chiappinelli, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

Break

10:00 a.m.-10:15 a.m.

Session 8: Immunotherapy on the Horizon

Session Chairperson: George Coukos, University Hospital of Lausanne, Epalinges, Switzerland
10:15 a.m.-12:15 p.m.

Immunotherapy opportunities and challenges in ovarian cancer
George Coukos

Protective immune networks in ovarian cancer
Brad Nelson, BC Cancer Foundation, Victoria, BC, Canada

NY-ESO-1 targeted immunotherapy
Kunle Odunsi, Roswell Park Cancer Institute, Buffalo, NY

Combinatorial immunotherapy using whole tumor antigen: Evidence from phase I trials
Lana E. Kandalaft, University of Pennsylvania School of Medicine, Philadelphia, PA

Closing Remarks and Departure

12:15 p.m.-12:30 p.m.